GFRAL (Glial cell line-derived neurotrophic factor family receptor alpha-like) is a transmembrane receptor crucial for mediating the metabolic effects of GDF15 (Growth Differentiation Factor 15). Its discovery was elucidated in 2017 by Mullican et al. through a comprehensive bioinformatic analysis of publicly available transcriptomic datasets, pinpointing GFRAL as a hypothalamic gene robustly induced by GDF15. This discovery underscored GFRAL's pivotal role in the central regulation of energy homeostasis.
Concomitantly, the development of a Human GFRAL Stable Cell Line - HEK293 emerged to facilitate further investigation into GFRAL's signaling mechanism and pharmacological modulation. Established through stable transfection of HEK293 cells with GFRAL-expressing constructs, this cell line provides a reliable tool for studying GDF15/GFRAL interactions and downstream signaling pathways. Such a cell model is invaluable for elucidating the physiological relevance and therapeutic potential of targeting the GDF15-GFRAL axis in metabolic regulation.
Growth differentiation factor 15 (GDF15) induces chemotherapy-related nausea, vomiting, and appetite loss by interacting with the GFRAL-RET receptor complex in hindbrain neurons. Researchers have identified GDF15 as a key factor in chemotherapy-induced nausea, emesis, and anorexia by binding to the GFRAL-RET receptor complex in hindbrain neurons. Targeting GDF15-mediated GFRAL-RET signaling shows promise in improving chemotherapy outcomes. Peptide-based antagonists like GRASP block GDF15-mediated RET recruitment. In vivo studies in rats demonstrate that GRASP attenuates GDF15-induced symptoms and synergizes with Ondansetron to further alleviate anorexia. These findings suggest GRASP as a potential treatment for chemotherapy-related malaise and other conditions associated with elevated GDF15 levels.
Figure 1. Flow cytometric analysis of GFRAL–HEK293 cells was conducted by researchers, revealing altered binding patterns in EHMT2 KO cells compared to control cells. HEK293 cells engineered with stable overexpression of human GFRAL were procured from Creative Biogene. (Borner T, et al., 2023)
1. Obesity research: Utilizing Human GFRAL Stable Cell Line - HEK293 to study the effects of GDF15 on energy expenditure and weight regulation in obese animal models.
2. Cancer biology: Investigating the role of GFRAL in cancer cachexia by analyzing the response of Human GFRAL Stable Cell Line - HEK293 to tumor-derived factors.
3. Metabolic disorders: Assessing the therapeutic potential of novel compounds targeting GFRAL signaling using Human GFRAL Stable Cell Line - HEK293 in vitro assays.
4. Drug discovery: Screening small molecule libraries for GFRAL modulators with anti-obesity effects employing Human GFRAL Stable Cell Line - HEK293 as a screening platform.
5. Neurobiology: Examining the neuroprotective properties of GFRAL ligands through Human GFRAL Stable Cell Line - HEK293-based assays in models of neurodegenerative diseases.
Customer Q&As
What considerations drove the choice of HEK293 cells for establishing the stable GFRAL cell line?
A: HEK293 cells were likely chosen due to their high transfection efficiency, robust growth characteristics, and suitability for expressing membrane-bound proteins like GFRAL, facilitating studies on its signaling and function.
How was the stability of GFRAL expression assessed and maintained in this HEK293 stable cell line?
A: Stability was likely confirmed through methods such as immunoblotting, flow cytometry, or functional assays assessing downstream signaling pathways, with continuous selection pressure applied.
Can you provide insights into the characterization of GFRAL expression in the HEK293 stable cell line, including its subcellular localization and ligand-binding properties?
A: Characterization may involve analysis of GFRAL localization, ligand-binding kinetics, downstream signaling cascades, and functional implications in metabolic regulation and energy homeostasis.
What quality control measures were implemented during the development of this stable cell line?
A: Quality control likely included screening for mycoplasma contamination, confirmation of stable transgene integration, and assessment of phenotypic stability and consistency.
How does the expression pattern and functional properties of GFRAL in this stable cell line relate to its physiological roles and relevance in metabolic regulation, appetite control, and potential therapeutic targeting?
A: Comparative analysis with in vivo models or clinical data helps validate the relevance of GFRAL expression in metabolic diseases such as obesity, diabetes, and cancer cachexia, guiding therapeutic research efforts.
Ask a Question
Customer Reviews
Eased GDF15 signaling study
This Human GFRAL Stable Cell Line is a lifesaver! Its stable expression in HEK293 cells has made studying GDF15 signaling a lot less daunting.
Lifesaver GFRAL expression
Using this cell line feels like having a guiding light! The stable GFRAL expression has clarified my research on metabolic regulation pathways and made my work more impactful.
Reliable GFRAL expression
So grateful for this Human GFRAL Stable Cell Line! Its reliable expression in HEK293 cells has brought clarity to my experiments and boosted my confidence in the results.
United Kingdom
04/29/2022
Confidence in results
Can't get over how much smoother my research has become with this cell line! The stable GFRAL expression has simplified my workflow and made studying metabolic regulation mechanisms a joy.
United Kingdom
03/06/2024
Smooth workflow with GFRAL
This Human GFRAL Stable Cell Line is a game-changer! Its consistent expression in HEK293 cells has unlocked new insights into metabolic regulation, making my research journey more rewarding.
Write a Review